Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
beta-amyloid levels are elevated in Down syndrome (DS) patients throughout life and are believed to cause Alzheimer's disease (AD) in adult members of this population. However, it is not known if beta-amyloid contributes to intellectual disability in younger individuals. We used a gamma-secretase inhibitor to lower beta-amyloid levels in young mice that model DS. This treatment corrected learning deficits characteristic of these mice, suggesting that beta-amyloid-lowering therapies might improve cognitive function in young DS patients.
Netzer
William J
WJ
Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA. netzerw@rockefeller.edu
Powell
Craig
C
Nong
Yi
Y
Blundell
Jacqueline
J
Wong
Lili
L
Duff
Karen
K
Flajolet
Marc
M
Greengard
Paul
P
D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007858:Learning; D008568:Memory; D051379:Mice; D008822:Mice, Transgenic
D016229:Amyloid beta-Peptides; D004791:Enzyme Inhibitors; D053829:Amyloid Precursor Protein Secretases